Investors Can Lead Unicycive Therapeutics Securities Fraud Lawsuit

Rosen Law Firm, a global investor rights law firm, has announced that purchasers of Unicycive Therapeutics, Inc. securities are being notified of an opportunity to lead a securities fraud lawsuit filed against the company. The lawsuit targets investors who purchased Unicycive securities between December 29, 2025, and June 29, 2026.

The complaint alleges that Unicycive made materially false and misleading statements and failed to disclose key information. Specifically, the suit claims the company had not inspected its third-party manufacturing vendor's facility or audited its compliance with current good manufacturing practices (cGMP). As a result, Unicycive allegedly lacked a reasonable basis to believe the vendor had resolved deficiencies previously cited by the U.S. Food and Drug Administration (FDA). The lawsuit asserts this created an undisclosed risk that FDA approval for the company's oxylanthanum carbonate (OLC) could be delayed.

Investors who purchased Unicycive securities during the specified class period and wish to be considered for the role of lead plaintiff must file a motion with the court by November 2, 2026. The lead plaintiff is a representative party who directs the litigation on behalf of other class members. Rosen Law Firm states that eligible investors may be able to recover compensation without incurring out-of-pocket expenses through a contingency fee arrangement.

Rosen Law Firm highlights its experience in securities class actions and its track record of recovering funds for investors. The firm encourages investors to select experienced counsel. Further details regarding the class action and how to participate can be found on the law firm's website.